Answers are grounded in this paper and cite their sources.
Validation study reveals AQoL-6D pairs effectively with EPIC-26 post-prostate cancer treatment, indicating its viability for deriving quality-adjusted life years in economic evaluations.
AQoL-6D can be used in combination with EPIC-26 in place of SF-12. Although EPIC-26 is not utility based, its popularity amongst clinicians and ability to discriminate between disease-specific characteristics and post-treatment outcomes in clinical trials makes it a candidate for use within cost-effectiveness analyses. The generic measure provides a holistic assessment of quality of life and is suitable for generating quality adjusted life years (QALYs).
No takes yet. Share an insight, caveat, or question.
Bulamu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: